Oncotarget

Clinical Research Papers:

A three-protein signature and clinical outcome in esophageal squamous cell carcinoma

Hui-Hui Cao, Shi-Yi Zhang, Jin-Hui Shen, Zhi-Yong Wu, Jian-Yi Wu, Shao-Hong Wang, En-Min Li _ and Li-Yan Xu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:5435-5448. https://doi.org/10.18632/oncotarget.3102

Metrics: PDF 1857 views  |   HTML 1986 views  |   ?  


Abstract

Hui-Hui Cao1,2,6,*, Shi-Yi Zhang3,*, Jin-Hui Shen4,*, Zhi-Yong Wu3, Jian-Yi Wu1,5, Shao-Hong Wang4, En-Min Li1,5 and Li-Yan Xu1,2

1 The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, Guangdong, P.R. China

2 Institute of Oncologic Pathology, Shantou University Medical College, Shantou, Guangdong, P.R. China

3 Departments of Oncology Surgery, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, Guangdong, P.R. China

4 Departments of Pathology, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, Guangdong, P.R. China

5 Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, Guangdong, P.R. China

6 Departments of Pathology, Zhuhai People’s Hospital, Zhuhai, Guangdong, P.R. China

* These authors contributed equally to this work

Correspondence:

En-Min Li, email:

Li-Yan Xu, email:

Keywords: ESCC, Kindlin-2, Myosin-9, three-protein signature, prognosis

Received: September 30, 2014 Accepted: December 28, 2014 Published: December 31, 2014

Abstract

Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3102